Article Per Year (5 Year)
p-Index From 2020 - 2025
3.096
P-Index
This Author published in this journals
All Journal Molecular and Cellular Biomedical Sciences (MCBS) Jurnal Respirologi Indonesia Jurnal Respirasi (JR) Sumatera Medical Journal AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh Respiratory Science Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI) The Journal of Society Medicine (JSOCMED)
Noni Novisari Soeroso
Department Of Pulmonolgy And Respiratory Medicine, Faculty Of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, Indonesia
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 18 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 18 Documents
Search

 1   2 
Proportion of Mutation of Epidermal Growth Factor Receptor (EGFR) Genes from Tissue Biopsy and Liquid Biopsy ctDNA in Lung Adenocarcinoma Hendra Taufik; Noni Novisari Soeroso; Setia Putra Tarigan; Erna Mutiara
Jurnal Respirologi Indonesia Vol 40, No 3 (2020)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v40i3.118

Abstract

Backgrounds: In recent years, circulating tumor DNA (ctDNA) has emerged as a specific and sensitive blood-based biomarker to detect EGFR mutations. This study aims to determine the diagnostic accuracy of ctDNA in detecting EGFR gene mutations in adenocarcinoma lung cancer. Methods: This study was a cross-sectional study with the subjects were adenocarcinoma lung cancer patients from histopathology or cytology examination and examined EGFR mutations from plasma tissue biopsy and ctDNA specimens from April 2018 to February 2019 in several hospitals in the Medan City. Results: There were 100 data have been collected, with male were 71 subjects and female were 29 subjects. Found 20 mutations, single mutations of tissue biopsy were 19 cases, del exon 19 were 12 cases, mutation in exon 21 (L858R) were 6 cases, mutation exon 21 (L861Q) was 1 case, del exon 19 and 21 (L861Q double mutations) was 1 case. From plasma ctDNA examination EGFR mutations were found 15 cases, del exon 19 were 12 cases and del exon 21 (L858R) were 3 cases. Conclusions: The highest proportion of EGFR mutations by sex were women from tissue biopsy or ctDNA, the most often frequency of EGFR mutations from tissue biopsy and ctDNA in single mutations and exons19. (J Respir Indo. 2020; 40(3): 150-5)
Differences of Interleukin-6 Serum Levels in Lung Cancer Patients and Healthy Individuals in Medan Dumasari Siagian; Noni Novisari Soeroso; Bintang Yinke Magdalena Sinaga; Putri C Eyanoer
Jurnal Respirologi Indonesia Vol 41, No 1 (2021)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v41i1.155

Abstract

Background: Interleukin-6 (IL-6) is a pro-inflammatory cytokines involved in the development of lung cancer. However, the association of IL-6 in lung cancer patients remains uncertain. The aim of this study was to analyze the difference of IL-6 serum levels in lung cancer patients and healthy individuals in Medan. Methods: This was a case-control study that included 42 lung cancer patients (case) and 42 healthy individuals (control) which was held in Haji Adam Malik General Hospital Medan. The examinations of IL-6 serum levels were conducted for all subjects using ELISA method. Differences of IL-6 serum levels in lung cancer patients and healthy individuals were analyzed using Spearman Correlation test. Results: The mean serum IL-6 levels in lung cancer patients was 45.99 pg/ml while in healthy individuals was 6.24 pg/ml. There was a significant difference of serum IL-6 levels in the lung cancer group compared to healthy individuals (P=0.0005;r=0.854). Conclusion: There was a statistically significant difference of IL-6 serum levels between lung cancer patients and healthy individuals.
The Relationship between Tyr113His Epoxidized Hydrolase Enzyme Gene Polymorphisms and the Incidence of Smoking Lung Cancer Lucia Aktalina; Amira Permatasari Tarigan; Noni Novisari Soeroso; Yahwardiah Siregar; Ozar Sanuddin
Jurnal Respirologi Indonesia Vol 38, No 2 (2018)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v38i2.163

Abstract

Background: This study aims to determine the relationship between the gene polymorphism of the enzyme Epoxid Hydrolase (EPHX) Tyr113His and the tendency of smokers to suffer from lung cancer. The EPHX Tyr113His gene polymorphism is a change in one nucleotide base of the EPHX gene to produce enzymes with decreased function by 50%. EPHX plays a role in the metabolism of chemical compounds in cigarette smoke, especially Benzo (a) Pyren (BaP), which becomes a carcinogen in the body. Methods: This study is a case-control study design conducted from October 2016 to February 2017. Venous blood was taken from 35 people with lung cancer at RSUP H Adam Malik Medan and 35 healthy smokers. The genotype examination of the EPHX gene was carried out using the PCR-RFLP method in the USU FK Integrated Laboratory. Results: The genotype frequency of heterozygous variant T/C and homozygous variant C/C in case groups was 83.3% and 16.7%, respectively. The frequency of the T allele in the case group was 41.67% and the C allele was 58.33%. Whereas in the control, the frequency was heterozygous variant T/C (80%) and homozygous variant C/C (20%). The frequency of the T allele in the control group was 40% and the C allele was 60%. There were no homozygous wildtype T/T genotypes in the two groups. There was no significant difference in the genetic distribution and allele distribution of the EPHX enzyme between case and control groups. Conclusion: There is no relationship between EPHX Tyr113His enzyme gene polymorphisms and the incidence of lung cancer in smoking. J Respir Indo 2018; 38(2): 93-9)
The Relationship of Genetic Polymorphism Micromal Epoxide Hydrolase (EPHX1) His139Arg and Lung Cancer Rosidah Hanum Hasibuan; Noni Novisari Soeroso; Setia Putra Tarigan; Yahwardiah Siregar; Erna Mutiara; Lucia Aktalina
Jurnal Respirologi Indonesia Vol 42, No 2 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v42i2.305

Abstract

Background: Microsomal epoxide hydrolase 1 (EPHX1) plays an important role in both activation and detoxification of polycyclic aromatic hydrocarbons (PAH) and aromatic amines. Polymorphism EPHX1 His139Arg in susceptibility to lung cancer has been reported with inconsistent outcomes. Aim of this study was to analyze the relationship between this polymorphism and lung cancer in smokers.Method: Consecutive sampling and case-control study was applied. Genotyping was performed by PCR-RFLP assay. The chi-square test with p<0.05 considered as significant.Results: Of all 84 subjects, in case and control groups, wild-type variant His139His were 34 (81%) and 30 (71.4%), heterozygote variant His139Arg were 8 (19%) and 12 (28.6%), there was no homozygote variant Arg139Arg identified. (p=0.36).Conclusion: The EPHX1 His139His represents a common polymorphism in both of subject groups. There is no association between His139Arg polymorphism of EPHX1 and lung cancer.
Programmed Death Ligand 1 (PD-L1) Expression in Lung Adenocarcinoma Patients Rahmat Hidayat; Noni Novisari Soeroso; Elisna Syahruddin; Dian Cahyadi; Setiaputra Setiaputra
Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v1i3.16

Abstract

Background: Programmed Death Ligand 1 (PD-L1) is a protein found in tumor cells that could inactivate T-cells. This research was done to identify the characteristics of lung adenocarcinoma patients to PD-L1 expression in Medan.  Method: Descriptive research with a cross-sectional design was used and the study was done for 12 months (January – December 2018). Sample’s collection was done at RSUP (Central Public Hospital) H. Adam Malik and the samples diagnosed with lung adenocarcinoma based on histopathological subtyping were sent to the laboratory of Dharmais Jakarta Hospital where the Ventana 22C3 Immunohistochemistry Staining was done. Results: Staining was done in 52 samples at Dharmais Jakarta Hospital and only 35 samples were deemed acceptable. In this study, participants’ ages ranged from 40 to 60 years, where the majority were male patients, 31 (88.6%) and 33 patients (82.5%) were at an advanced stage (III and IV). Conclusion: The study found that the PD-L1 expression was mostly observed in male at the age range of 40 – 60 years and stage IV lung adenocarcinoma patients with Tumour Proportion Score (TPS) of 1 – 49%.
The Association of Acquired Resistance EGFR Exon 20 T790M Mutation and Treatment Response in Lung Adenocarcinoma Patients Receiving EGFR-TKI: Relationship between Acquired Resistance T790M Mutation and RECIST 1.1 Muhammad Harbi Praditya; Noni Novisari Soeroso; Setia Putra Tarigan; Taufik Ashar
Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v2i2.32

Abstract

Background: Lung adenocarcinoma patients receiving EGFR-TKI may develop acquired resistance within 7-16 months of treatment initiation, which is characterized by the presence of exon 20 T790M mutations in treatment response patients and can be assessed objectively by CECT and then evaluated by RECIST 1.1. The purpose of this study is to look into the association between acquired resistance EGFR Exon 20 T790M mutation and treatment response in lung adenocarcinoma patients receiving EGFR-TKI. Method: This research is an analytic study with a retrospective cohort design carried out at the Oncology Polyclinic at Haji Adam Malik Hospital from October 2020 to January 2021 in all patients with adenocarcinoma lung cancer who were treated with EGFR-TKI for more than 6 months. After that, an evaluation was carried out based on RECIST 1.1 and then examined for EGFR mutations from liquid biopsy specimens in the form of circulating tumor plasma DNA (ct-DNA) with the droplet digital Polymerase Chain Reaction (ddPCR) method to detect EGFR exon 20 T790M mutations as a marker of acquired resistance. Results: It was found that the majority of subjects were female (64.5%), aged 20-69 years (58%), and non-smokers (67.7%). The most common EGFR mutation was exon 19 deletion (58.1%). The incidence of acquired resistance was found in 10 subjects (32.3%). The distribution of RECIST 1.1 results on positive acquired resistance includes progressive diseases of 35.2%; stable disease of 11.1%; partial response of 33.4%; and 100% complete response. Negative acquired resistance includes 64.8% progressive disease, 88.9% stable disease, 66.6% partial response, and 0% complete response (P=0.93). Conclusion: There is no significant association between the incidence of acquired resistance mutations EGFR exon 20 T790M and treatment response in patients with lung adenocarcinoma who received EGFR-TKI therapy.
Correlation between Genetic Polymorphism of CYP2A13 Genotype and Lung Cancer in Female Passive Smokers Nurul Ramadhani; Noni Novisari Soeroso; Setia Putra Tarigan; Putri Chairani Eyanoer; Hidayat Hidayat
Molecular and Cellular Biomedical Sciences Vol 6, No 2 (2022)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v6i2.246

Abstract

Background: Nicotine is metabolized to cotinine by cytochrome P450 enzyme, and this enzyme is involved in the activation of toxic and carcinogenic substances. The aim of this research was to assess the relationship between genetic polymorphism of CYP2A13 and lung cancer incidence in female passive smokers.Materials and methods: This research was a case-control study that involved 104 research subjects. Subjects were recruited through purposive sampling technique from 2 hospitals in Medan, North Sumatra, Indonesia. The case population consisted of female passive smokers with lung cancer and the control population consisted of female passive smokers without lung cancer. All research subjects underwent blood sampling for genomics DNA extraction and CYP2A13 genotyping by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Data was analyzed by conditional logistic regression by Epi Info 7.0 software.Results: Among 104 subjects, 26 (25%) individuals were heterozygous, 76 (73%) individuals were wild type, and 2 (2%) were mutant for the 257Cys allele. There was a significant correlation between CYP2A13 genotype and lung cancer incidence (p-value<0.05). Female passive smokers with CT genotype had 2.7 greater risk of developing lung cancer than those with CC genotype (wild type). The C allele had more frequency and 1.6 times higher risk of lung cancer compared to T allele with a wide confidence range (0.73–3.52).Conclusion: There was a significant correlation between CYP2A13 polymorphism and lung cancer incidence in female passive smokers.Keywords: polymorphism, CYP2A13, PCR-RFLP, female passive smoker, lung cancer
Association of CYP2A6 Genetic Polymorphism and Lung Cancer in Female Never Smokers R.A Henny Anggriani; Noni Novisari Soeroso; Setia Putra Tarigan; Putri Chairani Eyanoer; Hidayat Hidayat
Molecular and Cellular Biomedical Sciences Vol 6, No 2 (2022)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v6i2.232

Abstract

Background: The major significant factor that affected lung cancer development among female passive smokers is environmental tobacco smoke. Nicotine can be found in a never smoker population, such as a child whose father is a smoker. Lung carcinogenesis in never smoker populations is affected by nicotine metabolism by CYP2A6 gene, which encodes the main nicotine metabolizing-enzyme. The aim of this study was to assess the genetic polymorphism of CYP2A6 and its association with secondhand smokers among females who have suffered from lung cancer in North Sumatra population.Materials and methods: This study was a case-control study, composed of 53 case subjects and 46 control subjects that were involved through a purposive sampling technique from two hospitals in Medan. PCR-RFLP was used for the examination of CYP2A6 gene to determine the genotype. The data were analyzed with conditional logistic regression test using Epi Info 7.0 software.Results: The most common genotype of CYP2A6 detected in this study was *1B/*1B (40.4%), while *1B allele had the highest prevalence (55.5%). There was no significant association between CYP2A6 genotype (p-value=0.61) or alleles (p-value=0.25) and the incidence of lung cancer.Conclusion: There was no association between CYP2A6 polymorphism and the incidence of lung cancer in secondhand smoker females.Keywords: CYP2A6, PCR-RFLP, female secondhand smokers, lung cancer
Characteristics of EGFR Gene Mutation in Lung Adenocarcinoma at Adam Malik General Hospital Novita Margaretta Ambarita; Noni Novisari Soeroso; Setia Putra Tarigan; Fotarisman Zalukhu
Jurnal Respirologi Indonesia Vol 42, No 3 (2022)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v41i1.156

Abstract

Background: Epidermal growth factor (EGFR) is a transmembrane receptor that plays an important role in the development of cancer phenotypes. Some patients with lung cancer have genetic mutations. Several studies have found a close correlation of EGFR gene mutation with 15-20% of lung adenocarcinoma cases. This study aimed to determine the EGFR profile in adenocarcinoma lung cancer patients at Haji Adam Malik General Hospital.Methods: This was a prospective cohort study conducted at Haji Adam Malik General Hospital, Medan. This study used patients data for 3 years, starting from January 1, 2014 to D1ecember 31, 2016. The sample size in this study was 34 patients. The data were then analyzed using SPSS.Results: All patients were adenocarcinoma lung cancer patients with positive EGFR mutation. There were 9 subjects with EGFR mutation in exon 19; 11 subjects with exon 21 L858R mutation; and 3 subjects with exon 21 L861Q mutation. Meanwhile, there were 3 subjects with uncommon EGFR mutations, namely exon 18 mutation. Majority of subjects with exon 19 mutation were male, aged >60 years, smokers with mixed types of cigarettes and severe brinkmann index. In subjects with exon 21 L858R mutation, most of the patients were male, aged 50-60 years, smokers with mixed cigarette types and severe brinkmann index. The same characteristics were also observed in subjects with exon 18 mutation. However, for exon 21 L861Q mutation, the majority of subjects were female with varying ages, and were not smokers.Conclusion: Most of the study subjects profiles were male, aged over 60 years, smokers, with mixed types of cigarettes, and with severe Brinkman Index. The EGFR mutations most commonly occured in exon 21, followed by exon 19 (ins/del exon 19), exon 18, and a combination of 2 exons.
Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia Sita Andarini; Elisna Syahruddin; Nathaniel Aditya; Jamal Zaini; Ferry Dwi Kurniawan; Sabrina Ermayanti; Noni Novisari Soeroso; Sri Melati Munir; Andreas Infianto; Ana Rima; Ungky Agus Setyawan; Laksmi Wulandari; Haryati Haryati; Ida Ayu Jasminarti; Arif Santoso
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.455

Abstract

Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.
Co-Authors Amira Permatasari Tarigan Ana Rima Ana Rima Setijadi Andarini, Sita Andreas Infianto Arfiansyah, Mochammad Aris Ariantika, Ariantika Arieta, Lydia Arif Santoso Arif Santoso Asfriyati ,MKes Bintang Yinke Magdalena Sinaga Chen, Jery Dian Cahyadi Dumasari Siagian Elisna Syahruddin Elisna Syahruddin Ermayanti, Sabrina Ermayanti, Sabrina Erna Mutiara Erna Mutiara Febiyanti, Mica Ferry Dwi Kurniawan Fotarisman Zalukhu Gema Nazri Yanni Harahap, Putri Wulandari Haryati Haryati Haryati Haryati Hendra Taufik Hidayat Hidayat Hidayat, Moulid Ida Ayu Jasminarti Indra Buana Infianto, Andreas Jasminarti, Ida Ayu Kurniawan, Ferry Dwi Laksmi Wulandari Lambok Siahaan Lim, Darren Wan-Teck Lucia Aktalina Lucia Aktalina Muhammad Harbi Praditya Nathaniel Aditya Neny Pristiwati Harahap Novita Margaretta Ambarita Nurmaini Nurmaini Nurul Ramadhani Ozar Sanuddin Putra, Andika Chandra Putri C Eyanoer Putri Chairani Eyanoer, Putri Chairani R Lia Kusumawati R.A Henny Anggriani Rahayu Lubis Rahmat Hidayat Ritonga, Adewita Rosidah Hanum Hasibuan Santi Syafril Santoso, Andintia Aisyah Setia Putra Tarigan Setiaputra Setiaputra Setyawan, Ungky Agus Siregar, Kamal Basri Sita Andarini Sri Melati Munir Sri Melati Munir Syamsul Bihar Tarigan, Setia Putra Taufik Ashar Yahwardiah Siregar Yahwardiah Siregar Zaini, Jamal